India, Nov. 2 -- Edwards Lifesciences (EW) reported positive results from its CLASP II TR trial, showing that the PASCAL transcatheter valve repair system outperformed medical therapy alone in patients with tricuspid regurgitation, a heart valve condition that causes blood to flow backward through the heart.
Tricuspid regurgitation (TR) can lead to symptoms such as fatigue, shortness of breath and fluid buildup, often reducing quality of life and increasing the risk of heart failure.
The CLASP II TR study found that patients treated with the PASCAL system experienced significant improvements in both valve function and overall health status compared with those receiving medical therapy alone.
After one year, 80% of patients treated with t...